Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

FibroBiologics, Inc. - Common Stock (NQ:FBLG)

0.2518 -0.0032 (-1.25%)
Streaming Delayed Price Updated: 1:41 PM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,070,781
Open 0.2533
Bid (Size) 0.2507 (500)
Ask (Size) 0.2528 (200)
Prev. Close 0.2550
Today's Range 0.2501 - 0.2699
52wk Range 0.2400 - 2.710
Shares Outstanding 38,262,586
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
FibroBiologics Announces Payoff of Outstanding Debt
Repayment of convertible promissory notes strengthens balance sheet and eliminates further dilution from conversions 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire

Performance

YTD
-87.3%
-87.3%
1 Month
-36.2%
-36.2%
3 Month
-58.2%
-58.2%
6 Month
-70.4%
-70.4%
1 Year
-90.3%
-90.3%

More News

Read More
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
News headline image
Top movers in Monday's session ↗
Via Chartmill
News headline image
The market is filled with gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Present at Bio-Europe 2025
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Present at the 2025 ThinkEquity Conference
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
BioVie and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
Brag House and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
FibroBiologics to Present at the Advanced Wound Care Summit USA
From FibroBiologics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is FibroBiologics, Inc. - Common Stock publicly traded?
Yes, FibroBiologics, Inc. - Common Stock is publicly traded.
What exchange does FibroBiologics, Inc. - Common Stock trade on?
FibroBiologics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for FibroBiologics, Inc. - Common Stock?
The ticker symbol for FibroBiologics, Inc. - Common Stock is FBLG on the Nasdaq Stock Market
What is the current price of FibroBiologics, Inc. - Common Stock?
The current price of FibroBiologics, Inc. - Common Stock is 0.2518
When was FibroBiologics, Inc. - Common Stock last traded?
The last trade of FibroBiologics, Inc. - Common Stock was at 12/04/25 01:41 PM ET
What is the market capitalization of FibroBiologics, Inc. - Common Stock?
The market capitalization of FibroBiologics, Inc. - Common Stock is 9.63M
How many shares of FibroBiologics, Inc. - Common Stock are outstanding?
FibroBiologics, Inc. - Common Stock has 10M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.